Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
April 01, 2010 (Vol. 30, No. 7)

Calmune Tackles Difficult Antigenic Targets

Firm Strives to Exploit Antibody Structures Made by the Body

  • Click Image To Enlarge +
    Penetration of topically delivered AC8 Fab antibody into the cornea

    Conventional antibody discovery methods poorly detect antigens cloaked in carbohydrates or lipids. Scientists at Calmune in San Diego are creating new technology platforms that overcome such limitations to uncover potent antibodies against infectious viruses, bacteria, and fungi. “Calmune offers new ways to generate antibodies against targets that have not adequately been addressed by conventional technologies,” says president and CEO Anthony Williamson, Ph.D.

    Some of the technology under development at Calmune was licensed from the Scripps Research Institute, where Dr. Williamson was an associate professor. He left Scripps and co-founded Calmune in 2006 along with colleagues Dennis Burton, Ph.D., and Pietro Paolo Sanna, Ph.D. The three researchers collaborated at Scripps on investigations into human antibody responses to infectious pathogens using phage-display libraries.

    “We became aware that there were a number of antibodies elicited during the course of a natural infection, particularly viral infections, that were extremely potent biologically,” says Dr. Williamson. The men founded Calmune to exploit antibody structures that have arisen naturally and are a response to immunologically challenging antigens.

    A prime example is the company’s DXAb antibody discovery platform. Short for “domain exchange antibodies,” the process was first identified in a neutralizing antibody that binds to human immunodeficiency virus (HIV). Generally, antibodies bind poorly to carbohydrate antigens.

    This unusual antibody, however, recognizes carbohydrates on the surface of HIV and neutralizes the virus. Mutations in the antibody’s framework cause a domain exchange in the heavy chain variable regions, resulting in an unusual linear structure instead of the usual Y-shape of conventional antibodies. The altered structure contains an array of fixed and closely spaced combining sites that are ideal for recognition of repetitive carbohydrate residues on the surface of HIV.

    This rare linear structural motif evolved naturally in the body’s response to HIV infections. Calmune scientists are manipulating the structure to create high-affinity, fully human monoclonal antibodies that recognize carbohydrate groups on a variety of clinically important microorganisms.

    The approach could lead to new treatments for infectious diseases, since many pathogens use carbohydrates to shield themselves from the immune system. “This is a way to overcome that protection by designing extremely specific anticarbohydrate antibodies that could be directed against sugars found on the surfaces of pathogens,” notes Dr. Williamson.

    Another new platform, called Membrane Proximal Antibodies, is closely related to DXAb and also was discovered in HIV. Membrane Proximal Antibodies show a preference for binding to antigens associated with lipids on cell membranes. As with  carbohydrate recognition, most antibodies do not bind readily to lipid-associated antigens.

    Company scientists are working to preserve the general features of the novel antibody structures that predispose them to bind to lipids and carbohydrates, but they are changing the binding pockets to make antibodies specific for other pathogens. “We’re taking something designed by the ingenuity of human immune system and trying to harness it more generally to make antibodies against other infectious agents,” Dr. Williamson says.